Skip to main content

Month: July 2024

Danske Bank share buy-back programme: Transactions in week 27

Company announcement no. 29 2024  Group CommunicationsBernstorffsgade 40DK-1577 København VTel. +45 45 14 00 00 8 July 2024Danske Bank share buy-back programme: Transactions in week 27 On 2 February 2024, Danske Bank A/S announced a share buy-back programme for a total of DKK 5.5 billion, with a maximum of 70 million shares, in the period from 5 February 2024 to 31 January 2025, at the latest, as described in company announcement no. 2 2024. The programme is being carried out under Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Rules. The following transactions were made under the share buy-back programme in week 27:  Number of shares VWAP DKK Gross valueDKKAccumulated,...

Continue reading

Sydbank share buyback programme: transactions in week 27

        Company Announcement No 29/2024Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk8 July 2024  Dear Sirs Sydbank share buyback programme: transactions in week 27On 28 February 2024 Sydbank announced a share buyback programme of DKK 1,200m. The share buyback programme commenced on 4 March 2024 and will be completed by 31 January 2025. The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under the share buyback...

Continue reading

Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery

PRESS RELEASE Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discoverySynsight provides Iktos with an exclusive worldwide license to INSERM’s patented technology enabling high performance AI-driven in cellulo screening of modulators of protein-protein and RNA-protein interactions The merger further complements Iktos’ AI-based drug discovery platform, that currently includes generative AI design, Retrosynthesis, and AI-driven automated synthesis capabilities by adding the key step of automated biological testingParis, July 8th 2024 – Iktos, a company specializing in Artificial Intelligence (AI) and Robotics for new drug design, announces the acquisition of Synsight, a French biotech company applying AI and high-content cell imaging to the...

Continue reading

LEXIBOOK: 2023-24 ANNUAL RESULTS IN LINE WITH EXPECTATIONS: ANNUAL SALES AT €58.6M (+14.4%). EBIT AND NET RESULT UP RESPECTIVELY TO +6.0M€ AND +5.0M€ THANKS TO AN EXCEPTIONAL CONJUNCTION OF POSITIVE FACTORS.

                                             Courtabœuf, July 08, 2024 at 7:00 a.m.LEXIBOOK: 2023-24 ANNUAL RESULTS IN LINE WITH EXPECTATIONS: ANNUAL SALES AT €58.6M (+14.4%). EBIT AND NET RESULT UP RESPECTIVELY TO +6.0M€ AND +5.0M€ THANKS TO AN EXCEPTIONAL CONJUNCTION OF POSITIVE FACTORS. ENCOURAGING OUTLOOK FOR FY 2024-25 DESPITE UNCERTAINTIES ON THE IMPACT OF FREIGHT COSTS AND EXCHANGE PERIODS AND ON CONSUMPTION.Annual sales: a historic fiscal year after 4 years of growth. Over the full fiscal year, which grew by 13.3% in 22-23, sales rose by a further 14.4% to €58.6m, compared with €51.2m a year earlier.Against a backdrop of a 3.6% appreciation of the euro against the US dollar in 1 year, and a very significant reduction in freight costs, Group margins logically improved as Lexibook succeeded in maintaining its prices, or even...

Continue reading

VIRBAC: exceptional first-half growth and guidance raised for 2024

Compte tenu de la dynamique très positive de nos ventes observée sur le premier semestre (croissance du chiffre d’affaires attendue autour de 16% à taux de change constants1 et ~11% à taux de change et périmètre constants) qui devrait se poursuivre sur le second semestre, ainsi que d’un marché de la santé animale particulièrement porteur, la croissance du chiffre d’affaires 2024 à taux de change constants est attendue entre 12,5% et 14,5%1 (correspondant à une croissance désormais attendue de 7% à 9% à taux de change et périmètre constants). Le ratio de “résultat opérationnel courant avant amortissement des actifs issus d’acquisitions” sur “chiffre d’affaires” devrait se consolider autour de 16% à taux de change et périmètre constants. A périmètre réel, l’impact des acquisitions Sasaeah et Globion devrait être légèrement accrétif sur ce...

Continue reading

VIRBAC announces executive management changes

Sébastien Huron leaves the company, Habib Ramdani takes over while the Group recruits its next chief executive officerVirbac announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group’s executive management by September 30, 2024, to take a break from his professional life. The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to replace Sébastien Huron, while the appointments and compensation committee recruits the next chief executive officer. Backed by the board of directors, Habib will be able to count on the full support of the Group executive committee in executing the roadmap of our Virbac 2030 project. The board of directors warmly thanks Sébastien for the tremendous...

Continue reading

Corbion reports the progress of its € 20 million share buyback program 1 July – 5 July 2024

Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024. During the week of 1 July up to and including 5 July 2024 a total of 70,284 shares were repurchased at an average price of € 19.1228 for a total amount of € 1,344,029.87. To date, the total consideration for shares repurchased amounts to € 17,644,487.57 representing 88.82% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of the share buyback program on its website: https://www.corbion.com/Investor-relations/shareholder-information This overview contains detailed information on the daily amount of repurchased shares and individual share purchase transactions.AttachmentWeekly progress on Corbion share buyback program 1 July – 5 July...

Continue reading

Unifiedpost Group closes the earlier announced divestment of FitekIN and ONEA.

Press Release – Inside Information  La Hulpe, Belgium – 8 July 2024, 7:00 am. CET – Inside Information – Unifiedpost Group SA (Euronext Brussels: UPG) (“Unifiedpost, Group”), a leading provider of integrated business communications, today announces the successful closing of its previously announced divestment of the stand-alone products FitekIN and ONEA to Fitek Holding Oü, a company funded by Baltcap, for €7,2 million in cash. Fitek Holding Oü, funded by Baltcap, a Private Equity Fund in the Baltic States and a former shareholder of Fitek, along with part of the existing management team, acquired the stand-alone products FitekIN and ONEA, including current customer contracts and intellectual property. The transaction was completed on July 5, 2024.  Additionally, a mutual reselling agreement was established between Unifiedpost’s...

Continue reading

Q2 2024 Revenue Update

OSLO, Norway (8 July 2024) – Based on preliminary reporting from operating units, management of TGS ASA (“TGS”) expects IFRS revenues for Q2 2024 to be approximately USD 224 million, compared to USD 206 million in Q2 2023. POC revenues* are expected to be approximately USD 215 million, compared to USD 241 million in Q2 2023. POC multi-client revenues are estimated at approximately USD 115 million versus USD 129 million in Q2 2023, with early sales of USD 49 million, compared to USD 66 million in Q2 2023, and late sales of approximately USD 66 million, up from USD 63 million in Q2 2023. Multi-client investments were approximately USD 52 million, compared to USD 86 million in Q2 2023. Proprietary revenues are expected to be USD 100 million versus USD 113 million in Q2 2023. “Without any special sales events, such as licensing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.